The underlying epigenetic instability of cancers as well as compensatory epigenetic repression occurring in repeat regions that show DNA hypomethylation such as vulnerability derived from second level control loss from the SETDB1 pathway makes the likelihood of a wide therapeutic window between cancer and normal tissue high, but further work is needed to bring combination strategies into the clinic. Here, SETDB1 is linked to cancer.